Yup, it’s been a while since I posted, and starting off with a bad headline to boot.
Anyway, FOLD is going into phase 3 with their treatment for Fabry disease. I don’t see a short term upside on that, but the longer term upside is their ability to target diseases with genetically engineered treatments. If they can smooth that process out there is profit to be made as an investor. Being down 20.99% today, I have to tell myself that or sell and get over it.Cheap, Lazy Reference links: Yahoo! Finance, Wall Street Survivor, Motley Fool CAPS, TheStreet, Google Finance, MSN Money